SCHEMBL389029

SCHEMBL389029

N#Cc1ccc(C(=O)O)c(F)c1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 1/20 0.55
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49
XDH P47989 1/20 0.49
SLC22A12 Q96S37 1/20 0.49
GPR27 Q9NS67 1/20 0.48
PKM P14618 1/20 0.46
CXCR3 P49682 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
HTT P42858 1/20 0.43
RXRA P19793 1/20 0.42
THRB P10828 1/20 0.41
LMNA P02545 1/20 0.41
ALDH1A1 P00352 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
S1PR3 Q99500 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16534013 0.86 KIF11 (0.53) MAP2K1XDHSLC22A12CXCR3RXRA
SCHEMBL30361968 0.85 MAP2K1 (0.51) MAP2K1MEN1KMT2AXDHSLC22A12
SCHEMBL29286624 0.85 MEN1 (0.50) MAP2K1MEN1KMT2AGAAMAPT
SCHEMBL284291 0.85 MAP2K1 (0.51) MAP2K1MEN1KMT2AXDHSLC22A12
SCHEMBL646582 0.83 KMT2A (0.49) MAP2K1MEN1KMT2AGAAMAPT
SCHEMBL3176877 0.83 DGAT1 (0.55) MAP2K1MEN1KMT2AGAAMAPT
SCHEMBL10244858 0.83 KMT2A (0.52) MAP2K1MEN1KMT2AGAAMAPT
SCHEMBL3157619 0.82 XDH (0.53) MAP2K1MEN1KMT2AXDHSLC22A12
SCHEMBL409948 0.80 MEN1 (0.50) MAP2K1MEN1KMT2AGAAMAPT
SCHEMBL9081914 0.79 MAP2K1 (0.39) MAP2K1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 708 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118184679-A Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material 中国石油天然气股份有限公司 2024-06-14 CN claimed
CN-116426282-B Biotin modified rare earth doped inorganic material and preparation method thereof 深圳市光与生物科技有限公司 2024-04-12 CN claimed
CN-116426282-A Biotin modified rare earth doped inorganic material and preparation method thereof 深圳市光与生物科技有限公司 2023-07-14 CN claimed
EP-3551633-B1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2021-03-31 EP claimed
CN-108285465-B Metal organic framework material, preparation method thereof, modified metal organic framework material and preparation method thereof 南开大学 2020-06-26 CN claimed
WO-2007117482-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-10-18 WO claimed
CN-122036605-A Antagonists of GPR39 proteins 俄勒冈健康科学大学 2026-05-15 CN disclosed
EP-3887359-B1 NOVEL TETRAZINE COMPOUNDS FOR IN VIVO IMAGING UNIV COPENHAGEN (DK) 2026-05-06 EP disclosed
US-20260049074-A1 THIADIAZOLYL DERIVATIVES IDEAYA BIOSCIENCES, INC. (US) 2026-02-19 US disclosed
US-12509454-B2 Thiadiazolyl derivatives IDEAYA BIOSCIENCES, INC. (US) 2025-12-30 US disclosed
US-20250387379-A1 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS NFLECTION THERAPEUTICS INC (US) 2025-12-25 US disclosed
US-12497382-B2 GLP-1R modulating compounds GILEAD SCIENCES, INC. (US) 2025-12-16 US disclosed
US-12485157-B2 Method of treating COVID-19 PFIZER INC. (US) 2025-12-02 US disclosed
EP-1007037-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 2000-06-14 EP disclosed
US-5866592-A Fibrinogen receptor antagonist and pharmaceutical compositions comprising the same NIPPON STEEL CORPORATION (JP) 1999-02-02 US disclosed
WO-1999000127-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 1999-01-07 WO disclosed
EP-0852225-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND MEDICINAL PREPARATIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT NIPPON STEEL CORPORATION (JP) 1998-07-08 EP disclosed
EP-0800516-A1 FIBRINOGEN RECEPTOR ANTAGONISTS HAVING SUBSTITUTED (b)-AMINO ACID RESIDUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME NIPPON STEEL CORPORATION (JP) 1997-10-15 EP disclosed
WO-1996020172-A1 FIBRINOGEN RECEPTOR ANTAGONISTS HAVING SUBSTITUTED β-AMINO ACID RESIDUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME NIPPON STEEL CORPORATION (JP) 1996-07-04 WO disclosed
WO-1996001255-A1 3-(CYANOPHENYL)-PYRAZOLE DERIVATIVES AS HERBICIDES ZENECA LIMITED (GB) 1996-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049074-A1 THIADIAZOLYL DERIVATIVES POLH, POLM, POLD1 MAP2K1 2246/4885MEN1 4795/4885KMT2A 2910/4885
US-12485157-B2 Method of treating COVID-19 ACE2, ACE, TMPRSS2 MAP2K1 4833/4885MEN1 4373/4885KMT2A 2283/4885
US-12509454-B2 Thiadiazolyl derivatives POLD1, POLQ, DNA2 MAP2K1 1183/4885MEN1 3388/4885KMT2A 2518/4885
US-20250387379-A1 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS SUB1, AHR, NCOA3 MAP2K1 3307/4885MEN1 4314/4885KMT2A 1334/4885
US-12497382-B2 GLP-1R modulating compounds GLP1R, GIPR, GPR119 MAP2K1 2524/4885MEN1 1966/4885KMT2A 3870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.